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The Future Electronic Pharmaceutical Brain 
Steve Varghese 
 
Abstract: With the rise of technology in the healthcare setting, it is important to consider which form of technology will make the most beneficial 
change. The technology that can make that change is artificial intelligence. Artificial intelligence is being implemented more and more in our world, 
so it is the time for pharmacy to consider integrating it into its own field. 
 
 
he implementation of technology into healthcare is vastly growing. 
From Electronic Medical Records to automated medication 
dispensing systems, technology is the norm in every doctor’s office 
and hospital in the U.S. But there is one type of technology that is slowly 
making its way into healthcare that is completely changing the field - 
artificial intelligence. Artificial intelligence (AI) is a branch of computer 
science that focuses on building smart machines capable of performing 
tasks that would normally require human intelligence.1 This includes the 
ability to reason and learn from past experiences by trial and error. For 
example, a chess computer program will attempt multiple moves until 
it can reach checkmate. By making mistakes as it tries new moves, the 
computer avoids those errors in the future. So, when the program is 
about to make a previous mistake, it can recall that attempt and change 
the outcome. This simple memorization of individual items and 
procedures, known as rote learning, is relatively easy to integrate into 
computers. Eventually, the computer program is able to generalize 
outcomes, draw inferences appropriate to the situation, and 
systematically search through a range of possible actions in order to 
reach some predefined goal or solution.1 That is artificial intelligence: 
the ability to use different programs and past experiences to learn and 
solve a problem. Examples of AI currently used in every day life include 
Apple’s Siri function, spam filters in email accounts, Netflix's 
recommendation category, and Snapchat filters. So, what if this 
technology is used in healthcare? What impact would it have? One field 
of healthcare that could change drastically with the addition of AI is drug 
development. The implementation of AI into drug development could 
bring vast improvements to patient care. 
 
Drug development can be more efficient with artificial intelligence. 
Typically, it takes about two billion dollars and ten to fifteen years to 
develop a novel drug.2 Even after all that time and money, there is still 
a high risk that the drug will fail leaving all that time and money wasted. 
However, AI can change that by speeding up the research process, while 
reducing the risk within clinical trials.  
 
AI has shown it has the capabilities of performing quantitative structure-
activity relationship (QSAR) analysis.2 QSAR analysis can be used to find 
potent leading compounds by predicting the bioactivity of hit analogues 
(compounds that demonstrate promising therapeutics effects). This is 
mainly done through data collection, selection of molecular 
descriptions, and the establishment and application of mathematical 
models. AI uses multi-task neural networks which have been shown to 
outperform the single-task neural networks that are typically used. A 
neural network is a computer program that operates like the human 
brain’s natural neural network.1 It is a series of algorithms that identifies 
relationships in a large amount of data, using excitatory and inhibitory 
connections (which represent the neurons in the brain); in this case, it is 
the best starting point for developing a new drug. Being able to use a 
multi-task neural network means that AI can reach the result at a much 
faster rate than a single-task neural network. As a result, prediction 
performance for hit-to-lead optimization studies would vastly improve.  
 
Another step of drug development that artificial intelligence can 
optimize is de novo drug design. De novo drug design means designing 
new chemical entities to modulate the target of interest.2 Traditional de 
novo design methods generate new molecules from scratch, but they 
are difficult to synthesize due to the complexity of the molecular 
structure and the difficulty to evaluate their bioactivity. However, AI has 
been able to automatically generate new structures, including the 
desired properties and chemical structures, with higher predictive 
activity.3 AI has also been able to guide chemists in performing inverse 
synthetic analysis and eliminate unrealistic molecules in drug designs. In 
silico evaluation of absorption, distribution, metabolism, excretion, and 
toxicity (ADME/T) properties can also be done with AI. With this 
technology, the determination of ADME/T properties of a developing 
drug can be done at exponentially faster rates. Through multi-tasking 
neural networks, the prediction of these properties is improved and 
more accurate. These steps in drug design require a large amount of 
time and money, but with AI these excesses can be reduced by more 
than half. Not only does AI save money during drug development, it can 
also generate greater profit. According to the McKinsey Global Institute, 
big data and machine learning could potentially result in a market that 
generates $100 billion in annual sales.4 When it comes to drug 
development, AI technology has the potential to make more money 
while generating potential new drug therapies within a shorter amount 
of time. 
 
Artificial intelligence companies are already starting to collaborate with 
pharmaceutical and healthcare companies. DeepMind Technologies, a 
UK based AI company and subsidiary of Google, and the Royal Free 
London National Health Service (NHS) Foundation collaborated to assist 
in the management of acute kidney injury.4 This global project utilized 
AI and data from NHS patients to develop a model that can predict 
future acute kidney injuries and provide confident assessments leading 
to early treatment. Another company, Atomwise, a pioneer in 
healthcare AI, has worked with Harvard, Stanford, and pharmaceutical 
companies to invent new potential medications for 27 disease targets.4 
These examples are just two out of a dozen collaborations between AI 
and pharmaceutical companies currently underway. These 
collaborations can improve patient care by using machine learning with 
patient data, making it easier to determine a diagnosis and begin 
treatment sooner. As AI continues to improve in development and 
efficiency, more pharmaceutical companies will begin to implement this 
new technology into their business model. 
 
Completely implementing artificial intelligence into drug development 
will not be an easy task, as there are many challenges. First, AI is a fairly 
new type of technology. It has not been around long enough to ensure 
that it is foolproof; therefore, more tests need to be performed to assess 
its performance. Second, companies have concerns and are hesitant to 
adopt AI. In a 2019 study, researchers asked leaders and workers in 
multiple companies if they would implement AI into their companies, 
and while the majority said yes, many were reluctant. Reasons for not 
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implementing AI included a lack of skilled staff, concerns about safety, 
regulations, and compliance, budget constraints, and a mistrust of 
unvalidated technologies.5 Although all legitimate points, most can be 
addressed. Yes, training staff will require time, but the time saved by 
using AI is significantly less. While implementation of AI can be 
expensive, the upfront investment will ultimately yield significant profit. 
As time progresses and additional testing is done, more trust will be 
placed in AI, and its benefits in healthcare will be recognized. 
 
Despite its trials and tribulations, implementing AI into drug 
development will vastly improve pharmaceutical care and provide 
better patient outcomes. AI has the ability to optimize drug 
development by making it more efficient, effective, and economical. 
With these improvements, patients will be able to receive the best 
possible treatments. As AI continues to become mainstream, it is 
important for pharmaceutical companies to consider adopting it. Now is 
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